Chapters

Transcript

Video

What is the significance of the FDA approval of PD-1 inhibitors for tumors with MSI? What other canonical driver mutations -- BRAF, ALK, and others -- of similar significance are coming?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Prof. Jean-Yves Blay, MD, PhD

Prof. Jean-Yves Blay, MD, PhD

Professor of Medicine
Université Claude Bernard
Lyon, France
Scientific Director
Canceropole Lyon Rhône Alpes